press releases

Lysogene secures a €4.3 million non-dilutive financing from Bpifrance to support its development
Lysogene secures a €4.3 million non-dilutive financing from Bpifrance to support its development 150 150 Lysogene

Financing composed of a €3.0 million R&D innovation loan and a 1.3 million reimbursable advanceCash…

Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021
Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021 150 150 Lysogene

Paris, France — 18 October 2021 at 06:00 pm CET— Lysogene (FR0013233475 – LYS), a…

Lysogene Reports its Cash Position as of 30 September 2021
Lysogene Reports its Cash Position as of 30 September 2021 150 150 Lysogene

Cash and cash equivalents of €9.5 million1 as of 30 September 2021 Paris, France —…

LYSOGENE Reports First Half 2021 Financial Results and Provides Operational Update
LYSOGENE Reports First Half 2021 Financial Results and Provides Operational Update 150 150 Lysogene

In the first half 2021, Lysogene advanced and extended its development pipelineCash and cash equivalents…

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Second patient treated in the global adaptative-design clinical trial with LYS-GM101Ongoing enrollment of a total…

Lysogene Reports its Cash Position as of 30 June 2021
Lysogene Reports its Cash Position as of 30 June 2021 150 150 Lysogene

Cash and cash equivalents of €15.0 million1 as of 30 June 2021 Paris, France —…

Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis
Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Paris, France — 08 July 2021 at 06:00 pm CET — Lysogene (FR0013233475 – LYS),…

Half-year liquidity contract statement for LYSOGENE
Half-year liquidity contract statement for LYSOGENE 150 150 Lysogene

Paris, France — 05 July 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS),…

LYSOGENE releases the results from June 25, 2021 ordinary annual and extraordinary general meeting
LYSOGENE releases the results from June 25, 2021 ordinary annual and extraordinary general meeting 150 150 Lysogene

Shareholders approved all proposed resolutions Paris, France — 25 June 2021 at 06:00 pm CEST…

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome 150 150 Lysogene

Strengthening of Lysogene’s pipeline with a new drug candidate for a pathology with high unmet…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top